Related references
Note: Only part of the references are listed.PSMA PET/CT for tyrosine-kinase inhibitor monitoring in metastatic renal cell carcinoma
L. M. Mittlmeier et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
F-18-PSMA 1007 in Suspected Renal Cell Carcinoma
Fahad Marafi et al.
CLINICAL NUCLEAR MEDICINE (2020)
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update
Borje Ljungberg et al.
EUROPEAN UROLOGY (2019)
Developments in the use of tyrosine kinase inhibitors in the treatment of renal cell carcinoma
Jarred P. Reed et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2019)
Early assessment with 18F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab
Tadashi Tabei et al.
BMC CANCER (2019)
Improved identification of patients with oligometastatic clearcell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT
Alexa R. Meyer et al.
ANNALS OF NUCLEAR MEDICINE (2019)
Do biomarkers play a predictive role for response to novel immunotherapeutic agents in metastatic renal cell carcinoma?
Alessandra Raimondi et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2019)
FDG PET/CT for assessing tumour response to immunotherapy: Report on the EANM symposium on immune modulation and recent review of the literature
Nicolas Aide et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy
Anna Katharina Seitz et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Renal Cell Carcinoma Pseudoprogression with Clinical Deterioration: To Hospice and Back
Roy Elias et al.
CLINICAL GENITOURINARY CANCER (2018)
Check point inhibitors a new era in renal cell carcinoma treatment
Mohamed Alsharedi et al.
MEDICAL ONCOLOGY (2018)
Serum miR-122-5p and miR-206 expression: non-invasive prognostic biomarkers for renal cell carcinoma
Frauke G. Heinemann et al.
CLINICAL EPIGENETICS (2018)
Preclinical Evaluation of 18F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging
Jens Cardinale et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0
Wolfgang P. Fendler et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
Utility of 68Ga prostate specific membrane antigen - positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma
Shankar Siva et al.
JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY (2017)
Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18F-FDG PET/CT Imaging in Patients with Advanced Melanoma
Steve Y. Cho et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Lesley Seymour et al.
LANCET ONCOLOGY (2017)
RECIST 1.1-Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group
Lawrence H. Schwartz et al.
EUROPEAN JOURNAL OF CANCER (2016)
RECIST 1.1-Update and clarification: From the RECIST committee
Lawrence H. Schwartz et al.
EUROPEAN JOURNAL OF CANCER (2016)
Pilot study: use of gallium-68 PSMA PET for detection of metastatic lesions in patients with renal tumour
Handoo Rhee et al.
EJNMMI RESEARCH (2016)
Effect of furosemide administration before F-18 fluorodeoxyglucose positron emission tomography/computed tomography on urine radioactivity and detection of uterine cervical cancer
Andrea d'Amico et al.
NUCLEAR MEDICINE REVIEW (2014)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Richard L. Wahl et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Share Paper
